PARIS/LONDON (Reuters) - French drugmaker Sanofi-Aventis is preparing to sell its own generic version of the blockbuster heart medicine Plavix in France, a company spokesman said on Monday. Plavix, ...

News of the expanded indication comes during a showdown between the marketer/manufacturer of the drug, Bristol-Myers Squibb (BMS)/Sanofi-Aventis, and Canadian drug company Apotex, which started ...

LONDON (Reuters) - Sanofi-Aventis and Bristol-Myers Squibb , which are just recovering from defeating generic competition to their top-selling Plavix drug in the United States, now face a similar ...

Generic competition will decimate sales of the brand-name drugs and slash the cost to patients and companies that provide health benefits. Top drugs getting generic competition by September 2012 are ...

Bristol-Myers Squibb Co. (BMY) and Sanofi-Aventis (SNY) now have the upper hand in an upcoming patent trial over their blockbuster heart drug Plavix, if Thursday’s court injunction in the case is any ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. The Food and Drug Administration said Friday that it will require a new ...

As expected, Sanofi-Aventis has seen its fourth-quarter earnings take a hammering from generic competition to the antithrombotic Plavix and diabetes treatment Amaryl, but overall revenues were up ...

How the influx of generics is bad for drug makers but good for you. July 25, 2011— -- intro: Ten of the world's top-selling prescription drugs are about to get cheaper. Over the next 17 months, ...